99 episodes
Neurology Today in 5 American Academy of Neurology
-
- Health & Fitness
Joseph E. Safdieh, MD, FAAN, Editor-in-Chief of Neurology Today highlights the most noteworthy and newsworthy neurology stories in the issue.
-
When to withdraw life support for severe TBI, inflammatory markers score and stroke risk, application overload for neurology residency programs.
In this week’s podcast, Neurology Today’s editor-in-chief discusses a paper advising against prematurely withdrawing life support for severe TBI, data showing those with the highest composite score of inflammatory markers had a greater risk for stroke, original reporting stressing that residency programs and applicants need to adopt more strategic approaches to managing the overwhelming volume of applications.
This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. -
Code for ICH, new findings on Havana syndrome, distal symmetric polyneuropathy underdiagnosed in low income primary care clinics
In this week’s podcast, Neurology Today’s editor-in-chief discusses a push among neurocritical care experts to develop a code procedure for intracerebral hemorrhage, new findings showing people with Havana syndrome have functional neurologic disorder, and a study reporting distal symmetric polyneuropathy is more prevalent but less diagnosed in primary care clinics in low-income areas.
This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information. -
Surgical removal of hematoma in ICH, disparities in neurodiagnosis for epilepsy, inequities among female neurology researchers
In this week’s podcast, Neurology Today’s editor-in-chief discusses a new study reporting better outcomes with surgical removal of hematoma in intracerebral hemorrhage, disparities in access to diagnosis and care for epilepsy, and the challenges that remain for women in neurology research.
-
Generative AI for personal statements, Match Day and neurology, AHS statement on CGRP-targeting therapies
Neurology Today Editor-in-Chief Joseph E. Safdieh, MD, FAAN, highlights new articles that discuss program directors’ response to the use of generative AI for personal statements, the good news for neurology based on the 2024 Match Day, and the AHS statement on CGRP-targeting therapies as a game changer for migraine treatment.
-
ME/CFS and long COVID; negative outcomes for ALS drug; donanemab
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that explores an association between myalgic encephalomyelitis/chronic fatigue and long COVID; negative phase 3 findings on AMX0035 for ALS, and the pending approval of donanemab for Alzheimer’s disease.
-
BTK inhibitors for MS, lecanemab, neurologic adverse effects and COVID vaccine
Neurology Today Editor-in-Chief Joseph E. Safdieh,MD, FAAN, highlights new research that casts doubt on the future of BTK inhibitors for MS, an assessment of the cost-effectiveness of lecanemab, and findings that COVID vaccines are not significantly associated with adverse neurologic events.